GBA1 (Glucocerebrosidase) Protein

GBA1 (Glucocerebrosidase) Protein

<div class="infobox infobox-protein">
<h3>GBA1 (Glucocerebrosidase)</h3>
<table>
<tr><th>Protein Name</th><td>Glucocerebrosidase (GCase)</td></tr>
<tr><th>Gene</th><td>[GBA1](/genes/gba1)</td></tr>
<tr><th>UniProt</th><td>[P04062](https://www.uniprot.org/uniprot/P04062)</td></tr>
<tr><th>PDB Structures</th><td>1OGS, 2V3D, 3KIM, 5V3E</td></tr>
<tr><th>Molecular Weight</th><td>59.7 kDa (536 aa)</td></tr>
<tr><th>Subcellular Localization</th><td>Lysosome</td></tr>
<tr><th>Protein Family</th><td>Glycosylhydrolase family 30</td></tr>
<tr><th>Expression</th><td>Highest in liver, spleen, brain ([neurons](/entities/neurons), microglia)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">162 edges</a></td>
</tr>
</table>
</div>

GBA1 Overview

Overview

GBA1 (Glucocerebrosidase) Protein

<div class="infobox infobox-protein">
<h3>GBA1 (Glucocerebrosidase)</h3>
<table>
<tr><th>Protein Name</th><td>Glucocerebrosidase (GCase)</td></tr>
<tr><th>Gene</th><td>[GBA1](/genes/gba1)</td></tr>
<tr><th>UniProt</th><td>[P04062](https://www.uniprot.org/uniprot/P04062)</td></tr>
<tr><th>PDB Structures</th><td>1OGS, 2V3D, 3KIM, 5V3E</td></tr>
<tr><th>Molecular Weight</th><td>59.7 kDa (536 aa)</td></tr>
<tr><th>Subcellular Localization</th><td>Lysosome</td></tr>
<tr><th>Protein Family</th><td>Glycosylhydrolase family 30</td></tr>
<tr><th>Expression</th><td>Highest in liver, spleen, brain ([neurons](/entities/neurons), microglia)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">162 edges</a></td>
</tr>
</table>
</div>

GBA1 Overview

Overview

Glucocerebrosidase (GCase) is a lysosomal hydrolase encoded by the [GBA1](/genes/gba1) gene that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose. GBA1 mutations are the strongest genetic risk factor for [Parkinson's disease](/diseases/parkinsons-disease) and [dementia with Lewy bodies](/diseases/dementia-lewy-bodies), creating a crucial link between lysosomal storage disorders and neurodegenerative diseases[@sidransky2009].

Introduction

Glucocerebrosidase is a 59.7 kDa enzyme essential for glycolipid metabolism in the lysosome. The enzyme deficiency causes [Gaucher disease](/diseases/gaucher-disease), the most common lysosomal storage disorder, while heterozygous mutations dramatically increase the risk of developing synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and potentially Alzheimer's disease (AD)[@mazzulli2011].

Structure

Primary Structure

GBA1 encodes a 536-amino acid protein:

• Signal peptide (1-19): Directs protein to lysosome
• Propeptide (20-39): Cleaved during maturation
• Catalytic domain (40-536): Contains active site

Three-Dimensional Structure

GCase adopts a (β/α)₈ TIM barrel fold:

• Active site residues: Glu235 (nucleophile), Glu349 (acid/base)
• N-glycosylation sites: Asn59, Asn146, Asn190
• Saposin C binding site: Required for in vivo activity
• Dimer interface: Forms functional homodimer

Crystal Structures

Key PDB structures include:

• 1OGS: Native GCase structure
• 2V3D: Complex with inhibitor
• 3KIM: Gaucher disease mutant (N370S)
• 5V3E: GCase bound to glucosylceramide analog

Normal Function

Catalytic Activity

GCase catalyzes the hydrolysis of glucosylceramide (GlcCer):

Glucosylceramide + H₂O → Ceramide + Glucose

This reaction is essential for:

• Glycolipid catabolism
• Membrane turnover
• Lipid rafts maintenance

Physiological Roles

Tissue Distribution

• Highest expression: Liver, spleen, bone marrow
• Brain expression: Neurons, [astrocytes](/entities/astrocytes), [microglia](/cell-types/microglia-neuroinflammation)
• Subcellular: Lysosomal lumen (mature enzyme)

Disease Associations

Parkinson's Disease

GBA1 mutations are the most significant genetic risk factor for idiopathic PD[@schapira2014]:

| Mutation | Effect | PD Risk Increase |
|----------|--------|------------------|
| N370S | Reduced activity | 5-10x |
| L444P | Severe loss | 10-20x |
| R463C | Partial loss | 5-8x |
| E326K | Mild loss | 2-3x |

Mechanisms of Increased Risk

Clinical Features in GBA-PD

• Earlier onset age (mean 58 vs 62 years)
• More severe motor symptoms
• Greater cognitive impairment
• More rapid progression
• Higher prevalence of hallucinations

Dementia with Lewy Bodies

GBA1 mutations are a major risk factor for DLB[@clark2015]:

• 5-10x increased risk
• Earlier onset
• More severe Lewy body pathology
• Often comorbid with Alzheimer's pathology

Alzheimer's Disease

The relationship with AD is more complex:

• GCase activity reduced in AD brains
• May influence [amyloid-beta](/proteins/amyloid-beta) metabolism
• Interactions with [tau](/proteins/tau) pathology
• Shared lysosomal dysfunction pathway

Gaucher Disease

Homozygous GBA1 mutations cause Gaucher disease:

| Type | Features | Neurodegeneration |
|------|----------|-------------------|
| Type 1 | Non-neuronopathic | None |
| Type 2 | Acute neuronopathic | Severe, early death |
| Type 3 | Chronic neuronopathic | Progressive, survi |

• Glucosylceramide accumulation in macrophages
• Neuronopathic forms feature neurodegeneration

Molecular Mechanisms

GCase-α-Synuclein Interaction

GCase directly binds α-synuclein:

• Normal GCase: promotes lysosomal degradation of α-synuclein
• Mutant GCase: fails to clear α-synuclein
• Result: intracellular aggregation

Lysosomal Dysfunction

GCase deficiency leads to:

• Accumulation of GlcCer and glucosylsphingosine
• Impaired autophagic flux
• Decreased lysosomal acidity
• Mitochondrial dysfunction

Lipid Raft Alteration

Ceramide generation affects:

• Membrane microdomains
• Signal transduction
• Protein trafficking

Therapeutic Approaches

Pharmacological Chaperones

These small molecules stabilize mutant GCase[@aflaki2016]:

| Drug | Mechanism | Status |
|------|-----------|--------|
| Migalastat | Active site binding | Approved for Fabry |
| Ambroxol | Chaperone activity | Phase 2 trials |
| Eliglustat | Substrate reduction | Approved for Gaucher |

Enzyme Replacement Therapy

• Recombinant GCase (imiglucerase, velaglucerase)
• Does not cross [blood-brain barrier](/entities/blood-brain-barrier)
• Benefits systemic but not CNS manifestations

Gene Therapy

• AAV-mediated GBA1 delivery
• CRISPR-based approaches
• Ex vivo gene therapy using stem cells

Substrate Reduction Therapy

• Reduces glucosylceramide production
• Miglustat, eliglustat approved for Gaucher
• Potential for PD prevention

Small Molecule Activators

• GCase activators in development
• Target wild-type enzyme to enhance activity
• Potential combination with chaperones

Biomarker Potential

Enzyme Activity

• Blood GCase activity: Reduced in GBA-PD and DLB
• CSF GCase activity: Correlates with disease progression
• Non-invasive biomarker candidate

Protein Levels

• CSF GCase measurement
• Glucosylsphingosine as biomarker
• Monitors treatment response

Genetics

Mutation Spectrum

Over 400 GBA1 mutations identified:

• Severe mutations: L444P, D409H, V394L
• Mild mutations: N370S, E326K, R463C
• Complex alleles: Recombinant alleles

Genotype-Phenotype

• Two severe alleles → Gaucher disease
• One severe + one mild → Gaucher + parkinsonism
• One mild allele → increased PD risk

Animal Models

Mouse Models

• Gba1 KO: Lethal embryonic
• Gba1 conditional KO: Neurodegeneration phenotype
• Gba1 N370S KI: PD-like features

Zebrafish Models

• Gba1 knockdown: α-synuclein aggregation
• Useful for drug screening

Research Directions

Current Clinical Trials

• Ambroxol in PD (NCT02941833)
• Gene therapy trials (NCT05398982)
• Combination approaches

Biomarker Development

• GCase activity assays
• Glucosylsphingosine measurement
• Imaging markers

Key Publications

Background

The study of Gba1 (Glucocerebrosidase) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-references

• Gene: [GBA1 Gene](/genes/gba1) - Gene encoding this protein
• Diseases:
• [Parkinson's Disease](/diseases/parkinsons-disease) - Primary PD risk
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies) - Major risk factor
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Possible association
• [Gaucher Disease](/diseases/gaucher-disease) - Caused by homozygous mutations
• Proteins:
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Interacts with GCase
• [Parkin](/proteins/parkin-protein) - Mitophagy pathway
• [PINK1](/proteins/pink1-protein) - Mitophagy pathway
• Mechanisms:
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction) - Central mechanism
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein) - Pathological aggregation
• [Mitophagy Defects](/mechanisms/mitophagy) - Mitochondrial quality control

See Also

• [Proteins Index](/proteins)
• [Genes Index](/genes)
• [Mechanisms Index](/mechanisms)
• [Diseases Index](/diseases)

External Links

• UniProt: [P04062](https://www.uniprot.org/uniprot/P04062)
• PDB: [1OGS](https://www.rcsb.org/structure/1OGS)
• GeneCards: [GBA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GBA1)
• OMIM: [230800](https://omim.org/entry/230800)
• NIH Genetic Testing: [GBA1](https://www.ncbi.nlm.nih.gov/gene/2629)

References